Patients' characteristics before TIL therapy
Patient | Gender | At diagnosis | Diagnosis to ACT (y)* | Prior treatments for stage IV disease | |||||
---|---|---|---|---|---|---|---|---|---|
Age | Stage | Site of metastasis | Treatment (not incl. IL-2) | IL-2–based treatment | Response to IL-2 treatment | TTP (mo) | |||
Responders | |||||||||
05-LA | M | 39 | M1a | SC | 2 | Surgery | CB | PD | Na |
19-NS | M | 50 | IIb | Na | 16 | Taxol | CB | PD | Na |
03-MG | M | 26 | Ib | Na | 10 | CB | PD | Na | |
06-TS | M | 55 | III | Na | 5 | HD bolus | SD | 6 | |
09-SD | M | 44 | IIb | Na | 1 | CB | PD | Na | |
13-BS | M | 57 | IIb | Na | 4 | CB | SD | 7 | |
14-SV | M | 69 | III | Na | 2.3 | Surgery | CB | PD | Na |
16-SH | M | 38 | III | Na | 2.8 | Taxol | CB | PD | Na |
18-WR | F | 68 | III | Na | 2.2 | Surgery | CB | PR | 5 |
20-TY | M | 55 | III | Na | 3.3 | Surgery | CB | CR | 5 |
Median | 3.1 | 5.5 | |||||||
Nonresponders | |||||||||
01-AY | M | 51 | M1a | SC | 5.3 | CB | SD | 14 | |
07-ZR | M | 20 | III | Na | 1.8 | CB | PD | Na | |
08-RM | F | 31 | Ia | Na | 2.8 | CB | PR | 2 | |
12-VS | F | 36 | III | Na | 5.5 | Surgery | CB | SD | 2 |
02-PE | M | 33 | III | Na | 3 | Dacarbacine | CB | PD | Na |
04-BA | M | 41 | III | Na | 16.3 | Surgery | CB | PR | 16 |
10-BE | F | 48 | III | Na | 4.8 | CB | PD | Na | |
11-KB | M | 55 | III | Na | 2.4 | CB | PD | Na | |
15-SM | M | 52 | M1c | Liver, bone | Na | Taxol | CB | PD | Na |
17-ZD | F | 46 | Ib | Na | 22 | CB | PD | Na | |
Median | 4.8 | 8.0 | |||||||
P = 0.58 | P = 0.47 |
Abbreviations: TTP, time to progression; CB, chemobiotherapy consisting of IL-2, dacarbazine, and cisplatin; HD, high-dose; Na, not applicable.
↵*Years from diagnosis to adoptive cell transfer.